Harrow Inc (HROW)

개요 뉴스 가격 이력 옵션 체인 Financials HROW 왜 하락? 토론 예측 주식 분할

Relative Volume:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1079)

615.733.4731

1A BURTON HILLS BLVD, NASHVILLE, CA

최신 SEC 제출 서류

HROW's Discussions on Twitter

Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
HROW Harrow Inc	38.77	1.40B	272.30M	-5.14M	42.76M	-0.1635
TAK Takeda Pharmaceutical Co Adr	17.10	55.69B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.855	43.77B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.01	36.19B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.28	32.25B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	517.71	26.29B	3.17B	1.29B	1.01B	27.09

Harrow Inc Stock (HROW) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-07-11	개시	Cantor Fitzgerald	Overweight
2025-06-12	개시	BTIG Research	Buy
2025-06-10	개시	William Blair	Outperform
2025-02-06	개시	H.C. Wainwright	Buy
2024-12-04	재확인	B. Riley Securities	Buy
2024-04-11	개시	Craig Hallum	Buy
2022-09-08	재개	B. Riley Securities	Buy
2021-10-14	재개	B. Riley Securities	Buy
2021-09-24	개시	Aegis Capital	Buy
2021-07-02	개시	Ladenburg Thalmann	Buy

Harrow Inc 주식(HROW)의 최신 뉴스

Harrow Inc (HROW) 재무 분석

Harrow Inc 주식 (HROW) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
SILVERNAIL LAUREN P	Director	May 18 '26	Buy	31.00	1,000	31,000	1,000
BAUM MARK L	CHIEF EXECUTIVE OFFICER	May 14 '26	Buy	30.20	10,000	302,000	2,996,130
BOLL ANDREW R.	PRESIDENT AND CFO	May 14 '26	Buy	29.90	3,500	104,650	814,679
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,184	59,428
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000
BOLL ANDREW R.	PRESIDENT AND CFO	Dec 12 '25	Option Exercise	3.95	60,000	237,000	837,844
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Dec 12 '25	Option Exercise	3.95	180,000	711,000	3,066,124

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc 주식(HROW)의 최신 뉴스

Harrow Inc (HROW) Institutional Confidence - TradingKey

Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results - Stock Titan

Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Harrow, Inc. Revenue Breakdown – NASDAQ:HROW - TradingView

Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

TradingKey - TradingKey

Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

HROW|Harrow Inc|Price:39.409|Chg%:+0.959 - TradingKey

Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey

HROW|Harrow Inc|Price:37.470|Chg%:-0.980 - TradingKey

BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo

HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus

Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews

Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus

Samsung Bioepis, Harrow present SB11 biosimilar study results By Investing.com - Investing.com South Africa

Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus

Samsung Bioepis, Harrow present SB11 biosimilar study results - Investing.com India

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - The Manila Times

Samsung Bioepis and Harrow Present Interim Data from a - GlobeNewswire

Harrow presents studies on eye care products at medical meeting By Investing.com - Investing.com Nigeria

Harrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina Care - Quiver Quantitative

Harrow presents new clinical data supporting IH... - Pluang

Harrow presents studies on eye care products at medical meeting - Investing.com

Nearly 20,000 Injections: IHEEZO Finds No Evidence of Added Endophthalmitis Risk - Stock Titan

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting - GlobeNewswire

Harrow Health stock trades steady as recent earnings and product expansion frame the outlook - AD HOC NEWS

Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock RisesPre-Earnings Drift - dars.gov.et

Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 80 Tells Investors - GuruFocus

Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership - simplywall.st

Harrow stock rises on recent results and market value - Ad-hoc-news.de

HROW6348836 Bond Profile — Key Metrics - TradingView

HROW6348836 Bond Coupon Profile — Rate & Payments - TradingView

Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors - GuruFocus

Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW) - Seeking Alpha

Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - Moomoo

Harrow Inc. (HROW) Slips 1% But Holds Key Support Above $40Dividend Growth Stocks - DonanımHaber

Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛

HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et

HROW News | HARROW INC (NASDAQ:HROW) - ChartMill

Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare

Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm

Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Enterprise value to EBIT forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView

Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo

Harrow Inc (HROW) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Harrow Inc 주식 (HROW) 내부자 거래

HROW과 유사한 종목